+

WO1989004165A1 - Complement alimentaire de desintoxication - Google Patents

Complement alimentaire de desintoxication Download PDF

Info

Publication number
WO1989004165A1
WO1989004165A1 PCT/US1988/003591 US8803591W WO8904165A1 WO 1989004165 A1 WO1989004165 A1 WO 1989004165A1 US 8803591 W US8803591 W US 8803591W WO 8904165 A1 WO8904165 A1 WO 8904165A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
sugar
lyxose
fucose
arabitol
Prior art date
Application number
PCT/US1988/003591
Other languages
English (en)
Inventor
Joseph A. Haklitch
Albert T. Naito
Original Assignee
Haklitch Joseph A
Naito Albert T
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haklitch Joseph A, Naito Albert T filed Critical Haklitch Joseph A
Publication of WO1989004165A1 publication Critical patent/WO1989004165A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Definitions

  • This invention relates to food supplements which have the effect of ameliorating the effects of the ingestion of alcoholic beverages.
  • 2,321,113 appears to recommend a mixture of one-third ascorbic acid, one third D-glucose and one-third of a mixture of Japanese peppermint oil, eucalyptus oil, and aniseed oil as a sobering mixture but does not appear to quantify any result.
  • One object of the invention is to provide a substance, a food supplement, which has a rapid sobering effect or which reduces post drunkenness discomfort or both.
  • Another object is to provide such a supplement, which is inexpensive to make and use, is readily manufactured and packaged, has long shelf life, and does not have a disagreeable taste.
  • Another object is to provide such a substance in a form which can be dissolved in readily-available liquids, fruit juice or plain water, so that it can be ingested by an alcohol drinker at the place where he or she has been drinking.
  • a food supplement which converts the alcohol in the ingester's stomach into a different substance, which utilizes body chemistry to reduce blood alcohol to carbon dioxide and urea and which crosses the brain-blood barrier to restore neuro- receptor and neuro-transmitter equilibrium.
  • a material that provides those results It detoxifies alcohol in the stomach and blood in thirty minutes or less, and it restores normal motor function and sensory functions in seconds after being ingested.
  • the material that provides those actions is a combination of one or more of four "pure" sugars with one or more of a number of amino acids.
  • the sugars are L-fructose, L-mannitol, L-sorbitol and D ( + )glucose.
  • the term "pure” as applied to sugar herein means crystalline purity, 99 percent pure. The requirement for high purity is based upon both a need for purity and the fact that the character of impurities is unknown and some can negate the arabitol, D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, and L(-) lyxose.
  • the term "pure” as applied to sugar herein means crystalline purity, 99 percent pure.
  • the requirement for high purity is based upon both a need for purity and the fact that the character of impurities is unknown and some can negate the effectiveness of the sugar or the amino acids.
  • the amino acids are gluta ine, lysine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and taurine.
  • the amino acids may be those found in common foodstuffs such as orange juice, clam chowder, soy bean soup, sheep milk, and others, but for uniform and more predictable result it is preferred that the amino acid be incorporated in pure crystalline form having optical density of 20 degrees or less.
  • the degree of drunkenness to be overcome and the amount required in the practice of the invention depends in part on the amount of alcohol that was ingested. There is a level of alcohol intake below which the drinker does not require the invention. In terms of amount of sugar, that level is about 2.5 grams. More than 6 grams of sugar may produce the adverse side effects listed above and is not required to produce the sobering effect. Thus the range of sugar per serving is about 2.5 to 6 grams. When prepackaged, 2.5 to 3 grams per package is preferred. A drinker who needs more than 3 grams, may be given two packages.
  • acetylsalicylic acid induces the production of the enzymes which convert ethanol to acetaldehyde by stimulating production of alcohol dehydrogenase in the liver in the volatilization reaction:
  • the acetaldehyde is converted to acetic acid by the stimulation of the enzyme acetaldehyde dehydrogenase.
  • the acetic acid is further converted to a (2) carbon metabolite (CO2) by the enzyme carboxylase.
  • CO2 carbon metabolite
  • the addition of the acetylsalicylic acid apparently produces, by conjugation, an abundance of carb ⁇ xylase to accelerate conversion of the acetic acid to CO2.
  • the invention is not concerned with the specifics of the process and relies only on the fact the that alcohol in the blood and stomach can be eliminated as a consequence of ingestion of the ingredients of the inventive supplement.
  • the reaction with alcohol which has not left the stomach is described as follows, using fructose as the example:
  • amino acids listed above have been found to be effective in combination with the listed sugars. Amino acids not in that list have not been found to be effective. In terms of quantity required for effectiveness with sugar in the range 2.5 to 6 grams, the amino acids arginine, tryptophan and tyrosine have been found to be effective in the range 25 to 3000 milligrams. The others appear to be effective in the range from 25 to 50 milligrams. The three amino acids which are effective over the greatest range: arginine, tryptophan, and tyrosine, are preferred over the other amino acids. The smaller number represents the minimum amount for reasonable effectiveness, and the upper amount represents the quantity above which the desired effect tends not to be increased.
  • the preferred form of the invention is a combination of any one or more of the listed sugars and any one or more of the listed amino acids in a quantity such that for each measure of the sugar between 2.5 and 6 grams there is an accumulation of effective amounts to a total of about 480 milligrams or more.
  • the sugar and amino acid combination be provided in powdered rather than in capsule or pill form to minimize the possibility of choking by an inebriated user.
  • the lower limit for observable beneficial result is very low, five to ten milligrams of amino acid. However, tests indicate that at least 480 milligrams is required to insure restoration of motor and sensory functions to very inebriated subjects.
  • the preferred range of ingredients is 2.5 to 6 grams of pure form of one or more of the sugars listed above together with 480 to 3000 milligrams of pure, or foodstuff form, of one or more of the amino acids listed above. Within the list of amino acids, arginine, tryptophan, and tyrosine are preferred.
  • Example 1 The combination of 3 grams of pure sugar selected from, or consisting of a combination of sugars from, the group consisting of zylitol, D(+) galactose, D(+) lactose, D(+) xylose, dulcitol, wyo-insoitol, L(-) fructose, D(-) mannitol, sorbitol, D(+) glucose, D(+) arabinose, D(-) arabinose, celloboise, D(+) maltose, D(+) raffinose, L(+)rhamnose, D(+) melibiose, D(-) ribose, adonitol, D(+) arabitol, L(-) arabitol, D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, and L(-)
  • lysine arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and taurine.
  • Example 2 The combination of 3 grams of pure sugar selected from, or consisting of a combination of sugars from, the group consisting of zylitol, D(+) galactose, D(+) lactose, D(+) xylose, dulcitol, wyo-insoitol, L(-) fructose, D(-) mannitol.
  • sorbitol D(+) glucose, D(+) arabinose, D(-) arabinose, celloboise, D(+) maltose, D(+) raffinose, L(+)rhamnose, D(+) elibiose, D(-) ribose, adonitol, D(+) arabitol, L(-) arabitol, D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, and L(-) lyxose with 480 to 3000 milligrams of pure, crystalline amino acid consisting of any combination of, or any one of, the group of amino acids consisting of arginine, tryptophan, and tyrosine.
  • Example 3 The combination of 3 grams of pure sugar selected from, or consisting of a combination of sugars from, the group consisting of zylitol, D(+) galactose, D(+) lactose, D(+) xylose, dulcitol, wyo-insoitol, L(-) fructose, D(-) mannitol, sorbitol, D(+) glucose, D(+) arabinose, D(-) arabinose, celloboise, D(+) maltose, D(+) raffinose, L(+)rhamnose, D(+) melibiose, D(-) ribose, adonitol, D(+) arabitol, L(-) arabitol, D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, and L(-)
  • Example 4 The combination of 3 grams of pure sugar selected from, or consisting of a combination of sugars from, the group consisting of zylitol, D(+) galactose, D(+) lactose, D(+) xylose, dulcitol, wyo-insoitol, L(-) fructose, D(-) mannitol, sorbitol, D(+) glucose, D(+) arabinose, D(-) arabinose, celloboise, D(+) maltose, D(+) raffinose, L(+)rhamnose, D(+) melibiose, D(-) ribose, adonitol, D(+) arabitol, L(-) arabitol, D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, and L(-)
  • asparagine aspartic acid, cysteine, glutamic acid, glycine, histidine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and taurine.
  • acetylsalicylic acid is added at the rate of about three to six grains for each 2.5 to 3 grams of sugar. Also, the addition of acetylsalicylic acid has the added advantage that the resulting mixture also helps overcome the discomfort that is often experienced while overcoming alcohol intoxication. The addition of the acetylsalicylic acid to the basic mixture of the invention results in a product which is useful as a remedy for the after effects of alcohol intoxication even if ingested after the ingester is no longer intoxicated.
  • acetylsalicylic acid is added for each 2.5 grams of sugar up to a maximum of 12 grains of the acid.
  • all or a part of the amino acid may be added in the form of a fruit juice or other foodstuff which is rich in one or more of the operative amino acids.
  • Citric acid is an alternative to acetylsalicylic acid as a potentiator of the volatilization of alcohol.
  • the minimum amount for effectiveness is about ten percent by weight of the amount of sugar.
  • the inclusion of citric acid rather than acetylsalicylic acid has the advantage that the upper permissible limit is established by taste rather than by some deleterious effect.
  • Acetylsalicylic acid and citric acid may be combined such that the product includes an amount of acetylsalicylic acid which equals approximately 0.025 to 0.06 grains for each milligram in which the amount of acetic acid is less than 100 milligrams per gram of sugar.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Seasonings (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Un additif alimentaire qui a l'avantage d'améliorer les effets de la consommation de boissons alcoolisées comprend la combinaison d'un ou de plusieurs sucres du groupe constitué de zylitol, D(+) galactose, D(+) lactose, D(+) xylose, dulcitol, wyo-insoitol, L(-) fructose, D(+) mannitol, sorbitol, D(+) glucose, D(+) arabinose, D(-) arabinose, celloboise, D(+) maltose, D(+) raffinose, L(+) rhamnose, D(+) melibiose, D(-) ribose, adonitol, D(+) arabitol, L(-) arabitol, D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, et L(-) lyxose, et un ou plusieurs des acides aminés du groupe constitué de l'arginine, la glutamine, la lysine, l'asparagine, l'acide aspartique, la cystéine, l'acide glutamique, la glycine, l'hisdine, la leucine, la méthionine, la phényle alanine, la proline, la sérine, la thréonine, le triptophan, la tyrosine, la valine et la taurine en une quantité telle que pour chaque mesure de sucre entre 2,5 et 6 grammes, il y a une quantité cumulative d'acide aminé qui tombe dans la plage effective d'au moins l'un des acides aminés dans la combinaison où la plage effective dans le cas de l'arginine, l'asparagine, l'acide aspartique, la cytéine, l'acide glutamique, la sérine, la glycine, l'histidine, la leucine, la méthionine, la phényle alanine, la prolyne, la valine, la glutamine, la lysine et la taurine est de 25 à 50 milligrammes. Dans le cas de la thréonine, de triptophan et de la tyrosine, cette quantité est comprise entre 25 et 1500 milligrammes. Pour accélérer le processus de volatilisation, de l'acide acétique ou de l'acide acétylsalicylique, ou les deux, est ajouté.
PCT/US1988/003591 1987-10-19 1988-10-13 Complement alimentaire de desintoxication WO1989004165A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US109,597 1980-01-04
US10959787A 1987-10-19 1987-10-19
US23930388A 1988-09-01 1988-09-01
US239,303 1988-09-01

Publications (1)

Publication Number Publication Date
WO1989004165A1 true WO1989004165A1 (fr) 1989-05-18

Family

ID=26807138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/003591 WO1989004165A1 (fr) 1987-10-19 1988-10-13 Complement alimentaire de desintoxication

Country Status (2)

Country Link
EP (1) EP0336960A4 (fr)
WO (1) WO1989004165A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002586A3 (fr) * 1992-07-24 1994-03-17 Agricultural & Food Res Repression de l'expression d'un gene virulent
EP0631778A1 (fr) * 1993-06-28 1995-01-04 Miwon Co., Ltd. Utilisation de l'L-aspartate et de d'L-asparagine pour la prevention du toxiéité de l'alcool
EP0652012A1 (fr) * 1989-03-27 1995-05-10 Albert Naito Combinaison de sucres avec des acides aminés et autres composés
WO1995022260A1 (fr) * 1994-02-16 1995-08-24 University Of Leeds Boisson pour sportifs
EP0681789A1 (fr) * 1994-05-10 1995-11-15 Hoechst Aktiengesellschaft Edulcorant ayant un goût amélioré semblable au saccharose; procédé pour la préparation; ses applications
US5798371A (en) * 1995-01-13 1998-08-25 Komissarova; Irina Alexeevna Pharmaceutical composition endowed with an antialcoholic and nootropic effect
EP0894439A1 (fr) * 1997-07-22 1999-02-03 Cerestar Holding Bv Boissons améliorant les performances physiques
EP0922459A1 (fr) * 1997-12-12 1999-06-16 Ernst-Günter Prof. Dr. Dr. Afting Compositions pharmaceutiques comprenant de la D-galactose et leur utilisation
WO2000071145A1 (fr) * 1999-05-24 2000-11-30 Hee Jung Kim Composition permettant de soulager les symptomes lies a la 'gueule de bois' et d'eviter la destruction de cellules cerebrales
WO2001074367A1 (fr) * 2000-04-05 2001-10-11 Veniamin Abramovich Khazanov Composition pharmaceutique a base d'un compose anti-inflammatoire non steroide
WO2005089774A1 (fr) * 2004-03-18 2005-09-29 Tanabe Seiyaku Co., Ltd. D-ribose pour soulager des symptômes de type dépression
WO2009096817A2 (fr) * 2008-01-31 2009-08-06 Alla Chem, Llc Produit réduisant le degré d’intoxication aigue par l’alcool (d’ébriété) et procédé d'utilisation correspondant
RU2396076C1 (ru) * 2009-01-29 2010-08-10 Андрей Александрович Иващенко Средство, уменьшающее степень острой алкогольной интоксикации (опьянения) и обладающее антипохмельным действием, биологически активная добавка, фармацевтическая композиция, лекарственное средство и способ получения
WO2014177989A2 (fr) 2013-04-29 2014-11-06 Chigurupati Technologies Private Limited Toxicité réduite dans des boissons alcoolisées
WO2015066799A1 (fr) * 2013-11-06 2015-05-14 Jarrouj Salim Composition et procede pour accroitre la vitesse du metabolisme de l'alcool et prevenir les symptomes de la gueule de bois
WO2016203499A1 (fr) 2015-06-19 2016-12-22 Chigurupati Harsha Composition de boisson synergique
WO2019035953A1 (fr) * 2017-08-18 2019-02-21 Calwood Nutritionals, Llc Compositions et procédés d'augmentation de la masse musculaire et de la résistance musculaire, de traitement de la peau, de réduction de l'usure et de la dégradation dues au vieillissement et à l'exposition et d'amélioration de la récupération d'un stress tel qu'un exercice et un traumatisme

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115572A (en) * 1977-02-03 1978-09-19 American Cyanamid Company Imidazo-[1,5-d]-as-triazin-1(2H)-ones and method of ameliorating asthma
US4212893A (en) * 1978-02-10 1980-07-15 Honey Bee Corporation Acidified whole milk beverage and method of preparation
US4500515A (en) * 1981-04-13 1985-02-19 Libby Alfred F Method for treating alcohol and drug addicts
US4582705A (en) * 1982-07-12 1986-04-15 Leonard Primes Composition for detoxification
US4596825A (en) * 1984-08-20 1986-06-24 Ajinomoto Co., Inc. Method of treating liver disturbances resulting from alcohol consumption and a composition therefor
US4647453A (en) * 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
US4753804A (en) * 1984-12-12 1988-06-28 Boehringer Biochemica S.P.A. Granular dietetic product based on amino acids and process for their preparation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0087068A1 (fr) * 1982-02-12 1983-08-31 Thomas Moses Dr. Beck Supplément d'aliments

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115572A (en) * 1977-02-03 1978-09-19 American Cyanamid Company Imidazo-[1,5-d]-as-triazin-1(2H)-ones and method of ameliorating asthma
US4212893A (en) * 1978-02-10 1980-07-15 Honey Bee Corporation Acidified whole milk beverage and method of preparation
US4500515A (en) * 1981-04-13 1985-02-19 Libby Alfred F Method for treating alcohol and drug addicts
US4582705A (en) * 1982-07-12 1986-04-15 Leonard Primes Composition for detoxification
US4596825A (en) * 1984-08-20 1986-06-24 Ajinomoto Co., Inc. Method of treating liver disturbances resulting from alcohol consumption and a composition therefor
US4647453A (en) * 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
US4753804A (en) * 1984-12-12 1988-06-28 Boehringer Biochemica S.P.A. Granular dietetic product based on amino acids and process for their preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0336960A4 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0652012A1 (fr) * 1989-03-27 1995-05-10 Albert Naito Combinaison de sucres avec des acides aminés et autres composés
WO1994002586A3 (fr) * 1992-07-24 1994-03-17 Agricultural & Food Res Repression de l'expression d'un gene virulent
EP0631778A1 (fr) * 1993-06-28 1995-01-04 Miwon Co., Ltd. Utilisation de l'L-aspartate et de d'L-asparagine pour la prevention du toxiéité de l'alcool
US5389359A (en) * 1993-06-28 1995-02-14 Miwon Co., Ltd. Pharmaceutical preparation containing L-aspartate or L-asparagine for preventing ethanol toxicity, and process for preparation thereof
WO1995022260A1 (fr) * 1994-02-16 1995-08-24 University Of Leeds Boisson pour sportifs
CN1078057C (zh) * 1994-02-16 2002-01-23 利兹大学 运动饮料
US6180155B1 (en) 1994-05-10 2001-01-30 Nufrinova Gmbh Sweetener having an improved sucrose-like taste and process for the preparation thereof and use thereof
EP0681789A1 (fr) * 1994-05-10 1995-11-15 Hoechst Aktiengesellschaft Edulcorant ayant un goût amélioré semblable au saccharose; procédé pour la préparation; ses applications
US5798371A (en) * 1995-01-13 1998-08-25 Komissarova; Irina Alexeevna Pharmaceutical composition endowed with an antialcoholic and nootropic effect
US6296892B1 (en) 1997-07-22 2001-10-02 Cerestar Holding B.V. Beverages for enhanced physical performance
EP0894439A1 (fr) * 1997-07-22 1999-02-03 Cerestar Holding Bv Boissons améliorant les performances physiques
EP0922459A1 (fr) * 1997-12-12 1999-06-16 Ernst-Günter Prof. Dr. Dr. Afting Compositions pharmaceutiques comprenant de la D-galactose et leur utilisation
WO2000071145A1 (fr) * 1999-05-24 2000-11-30 Hee Jung Kim Composition permettant de soulager les symptomes lies a la 'gueule de bois' et d'eviter la destruction de cellules cerebrales
WO2001074367A1 (fr) * 2000-04-05 2001-10-11 Veniamin Abramovich Khazanov Composition pharmaceutique a base d'un compose anti-inflammatoire non steroide
EA012323B1 (ru) * 2000-04-05 2009-08-28 Вениамин Абрамович ХАЗАНОВ Фармацевтическая композиция на основе нестероидного противовоспалительного средства
WO2005089774A1 (fr) * 2004-03-18 2005-09-29 Tanabe Seiyaku Co., Ltd. D-ribose pour soulager des symptômes de type dépression
JP2007529409A (ja) * 2004-03-18 2007-10-25 田辺製薬株式会社 うつ様症状改善剤
JP4754484B2 (ja) * 2004-03-18 2011-08-24 田辺三菱製薬株式会社 うつ様症状改善剤
WO2009096817A2 (fr) * 2008-01-31 2009-08-06 Alla Chem, Llc Produit réduisant le degré d’intoxication aigue par l’alcool (d’ébriété) et procédé d'utilisation correspondant
WO2009096817A3 (fr) * 2008-01-31 2009-09-24 Алла Хем, Ллс Produit réduisant le degré d’intoxication aigue par l’alcool (d’ébriété) et procédé d'utilisation correspondant
RU2396076C1 (ru) * 2009-01-29 2010-08-10 Андрей Александрович Иващенко Средство, уменьшающее степень острой алкогольной интоксикации (опьянения) и обладающее антипохмельным действием, биологически активная добавка, фармацевтическая композиция, лекарственное средство и способ получения
US10039776B2 (en) 2013-04-29 2018-08-07 Harsha Chigurupati Hepato-protective beverage composition
US9149491B2 (en) 2013-04-29 2015-10-06 Harsha Chigurupati Reduced toxicity in alcoholic beverages
WO2014177989A2 (fr) 2013-04-29 2014-11-06 Chigurupati Technologies Private Limited Toxicité réduite dans des boissons alcoolisées
WO2015066799A1 (fr) * 2013-11-06 2015-05-14 Jarrouj Salim Composition et procede pour accroitre la vitesse du metabolisme de l'alcool et prevenir les symptomes de la gueule de bois
WO2016203499A1 (fr) 2015-06-19 2016-12-22 Chigurupati Harsha Composition de boisson synergique
US10456359B2 (en) 2015-06-19 2019-10-29 Harsha Chigurupati Synergistic beverage composition
WO2019035953A1 (fr) * 2017-08-18 2019-02-21 Calwood Nutritionals, Llc Compositions et procédés d'augmentation de la masse musculaire et de la résistance musculaire, de traitement de la peau, de réduction de l'usure et de la dégradation dues au vieillissement et à l'exposition et d'amélioration de la récupération d'un stress tel qu'un exercice et un traumatisme
US11285124B2 (en) 2017-08-18 2022-03-29 Calwood Nutritionals, Llc Compositions and methods for increasing muscle mass and strength, treating skin, reducing wear and degradation from aging and exposure and improving recovery from stress such as exercise and trauma
US12201595B2 (en) 2017-08-18 2025-01-21 Calwood Nutritionals, Llc Compositions and methods for increasing muscle mass and strength, treating skin, reducing wear and degradation from aging and exposure and improving recovery from stress such as exercise and trauma

Also Published As

Publication number Publication date
EP0336960A4 (fr) 1990-02-20
EP0336960A1 (fr) 1989-10-18

Similar Documents

Publication Publication Date Title
WO1989004165A1 (fr) Complement alimentaire de desintoxication
EP0448895B1 (fr) Utilisation d'un système d'administration non alcoolisé pour ingrédients actifs qui sont ingérés par voie orale
US6406717B2 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
US4703045A (en) Therapeutic compositions for the treatment of hangover
EP0983726B1 (fr) Composition contenant des acides aminés et du tréhalose
CA2242646C (fr) Composition d'acides amines
WO2010118405A2 (fr) Compositions et procédés permettant d'atténuer les symptômes de la gueule de bois
JPH03128318A (ja) 筋力持続剤，滋養強壮剤，輸液用剤，栄養補給剤，疲労回復剤及び乳酸生成調節剤
EP0449787A2 (fr) Compositions pharmaceutiques, diétÀ©tiques ou vétérinaires à activité eumétabolique
US4006219A (en) Composition and method for countering effects of alcohol consumption
AU2003268700A1 (en) Amino acid compositions for improving central functions
JPH0352810A (ja) 血液脳関門を通過する物質
JPH05339148A (ja) 血液脳関門を通過する物質
US20010039264A1 (en) Amino acid-trehalose composition
JP3553992B2 (ja) 代謝調節剤
JP3228534B2 (ja) 血中アルコール濃度低下用組成物
JPH06336432A (ja) アドレナリン及びノルアドレナリン分泌促進組成物
BE1011395A5 (fr) Composition et utilisation.
FR2635264A1 (fr) Compositions pharmaceutiques et/ou dietetiques contenant de la l-carnitine et de la l-lysine
JP4163801B2 (ja) アルコール代謝促進作用物
Holder et al. Behavioral assessment of the toxicity of aspartame
JPH11158075A (ja) 膵機能調節剤
JP3380287B2 (ja) 血中アルコール濃度上昇阻害飲料
JP2001048794A (ja) 桑の葉由来粉末およびカキ由来粉末の混合物を含むｎｉｄｄｍ治療用の医薬組成物および健康食品
JP4435882B2 (ja) アルコール吸収抑制組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): DK JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT NL SE

WWE Wipo information: entry into national phase

Ref document number: 1988910286

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1988910286

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1988910286

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载